相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
R. Condorelli et al.
ANNALS OF ONCOLOGY (2018)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
First-line treatment disruption among post-menopausal women with HR+/HER2-breast cancer: a retrospective US claims study
Derek H. Tang et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies
Adam M. Brufsky
CANCER TREATMENT REVIEWS (2017)
Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States
Angela B. Mariotto et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2017)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Optimal management of hormone receptor positive metastatic breast cancer in 2016
Tomas Reinert et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
Julia A. Beaver et al.
FUTURE ONCOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
Montserrat Vera-Llonch et al.
BMC CANCER (2011)
Healthcare costs in postmenopausal women with hormone-positive metastatic breast cancer
Maureen J. Lage et al.
JOURNAL OF MEDICAL ECONOMICS (2010)